Loading
The umbrella term for low blood counts of any kind (white cells, red cells, platelets) when treatment suppresses the bone marrow. Most chemotherapy causes it temporarily; radioligands, CAR-T and some pills cause longer-lasting versions.
Myelosuppression is the shared toxicity of cytotoxic chemotherapy, conditioning regimens, lymphodepletion, radioligand therapy (177Lu-PSMA, PRRT) and a range of targeted agents, graded per lineage by CTCAE; pancytopenia means all three lineages are low. Blood counts before each cycle gate treatment, and delays and dose reductions are the standard responses. After CAR-T, prolonged and biphasic cytopenias (ICAHT) affect a third of patients and drive infection deaths months after infusion; lymphopenia is a marker of poorer immunotherapy outcomes. Therapy-related MDS is the late, permanent form of marrow injury.
Shares Blood counts that do not come back after CAR-T: ICAHT, Rebuilding an immune system: the timeline, lineage by lineage, Infection risk after transplant and cell therapy, phase by phase, and the prophylaxis that follows it, Hypogammaglobulinaemia and infection risk after B-cell therapies.
Shares Iron overload after transplant, Blood counts that do not come back after CAR-T: ICAHT, When steroids fail: ruxolitinib for steroid-refractory GvHD, Rebuilding an immune system: the timeline, lineage by lineage.
Shares When steroids fail: ruxolitinib for steroid-refractory GvHD, Rebuilding an immune system: the timeline, lineage by lineage, Infection risk after transplant and cell therapy, phase by phase, and the prophylaxis that follows it.
Shares Rebuilding an immune system: the timeline, lineage by lineage, Infection risk after transplant and cell therapy, phase by phase, and the prophylaxis that follows it.
Shares Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia), Systemic mastocytosis.
Shares Rebuilding an immune system: the timeline, lineage by lineage, Infection risk after transplant and cell therapy, phase by phase, and the prophylaxis that follows it, Hypogammaglobulinaemia and infection risk after B-cell therapies.
Shares Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia), Systemic mastocytosis.
Shares Febrile neutropenia, Neutropenia.